243 related articles for article (PubMed ID: 19811954)
1. Modulation of the colonic epithelial cell responses and amelioration of inflammation by CD80 blockade in TNBS colitis.
Srinivasan M; Summerlin DJ
Clin Immunol; 2009 Dec; 133(3):411-21. PubMed ID: 19811954
[TBL] [Abstract][Full Text] [Related]
2. Hapten-induced model of murine inflammatory bowel disease: mucosa immune responses and protection by tolerance.
Elson CO; Beagley KW; Sharmanov AT; Fujihashi K; Kiyono H; Tennyson GS; Cong Y; Black CA; Ridwan BW; McGhee JR
J Immunol; 1996 Sep; 157(5):2174-85. PubMed ID: 8757344
[TBL] [Abstract][Full Text] [Related]
3. A transient breach in the epithelial barrier leads to regulatory T-cell generation and resistance to experimental colitis.
Boirivant M; Amendola A; Butera A; Sanchez M; Xu L; Marinaro M; Kitani A; Di Giacinto C; Strober W; Fuss IJ
Gastroenterology; 2008 Nov; 135(5):1612-1623.e5. PubMed ID: 18765239
[TBL] [Abstract][Full Text] [Related]
4. Amelioration of immune-mediated experimental colitis: tolerance induction in the presence of preexisting immunity and surrogate antigen bystander effect.
Gotsman I; Shlomai A; Alper R; Rabbani E; Engelhardt D; Ilan Y
J Pharmacol Exp Ther; 2001 Jun; 297(3):926-32. PubMed ID: 11356912
[TBL] [Abstract][Full Text] [Related]
5. Immune modulatory treatment of trinitrobenzene sulfonic acid colitis with calcitriol is associated with a change of a T helper (Th) 1/Th17 to a Th2 and regulatory T cell profile.
Daniel C; Sartory NA; Zahn N; Radeke HH; Stein JM
J Pharmacol Exp Ther; 2008 Jan; 324(1):23-33. PubMed ID: 17911375
[TBL] [Abstract][Full Text] [Related]
6. Redirection of regulatory T cells with predetermined specificity for the treatment of experimental colitis in mice.
Elinav E; Waks T; Eshhar Z
Gastroenterology; 2008 Jun; 134(7):2014-24. PubMed ID: 18424268
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-25 inhibits interleukin-12 production and Th1 cell-driven inflammation in the gut.
Caruso R; Sarra M; Stolfi C; Rizzo A; Fina D; Fantini MC; Pallone F; MacDonald TT; Monteleone G
Gastroenterology; 2009 Jun; 136(7):2270-9. PubMed ID: 19505427
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease.
Abad C; Martinez C; Juarranz MG; Arranz A; Leceta J; Delgado M; Gomariz RP
Gastroenterology; 2003 Apr; 124(4):961-71. PubMed ID: 12671893
[TBL] [Abstract][Full Text] [Related]
9. CD80 blockade enhance glucocorticoid-induced leucine zipper expression and suppress experimental autoimmune encephalomyelitis.
Dudhgaonkar SP; Janardhanam SB; Kodumudi KN; Srinivasan M
J Immunol; 2009 Dec; 183(11):7505-13. PubMed ID: 19917693
[TBL] [Abstract][Full Text] [Related]
10. Keratin-8-deficient mice develop chronic spontaneous Th2 colitis amenable to antibiotic treatment.
Habtezion A; Toivola DM; Butcher EC; Omary MB
J Cell Sci; 2005 May; 118(Pt 9):1971-80. PubMed ID: 15840656
[TBL] [Abstract][Full Text] [Related]
11. MIP-3alpha neutralizing monoclonal antibody protects against TNBS-induced colonic injury and inflammation in mice.
Katchar K; Kelly CP; Keates S; O'brien MJ; Keates AC
Am J Physiol Gastrointest Liver Physiol; 2007 May; 292(5):G1263-71. PubMed ID: 17272517
[TBL] [Abstract][Full Text] [Related]
12. Adipose-derived mesenchymal stem cells alleviate experimental colitis by inhibiting inflammatory and autoimmune responses.
González MA; Gonzalez-Rey E; Rico L; Büscher D; Delgado M
Gastroenterology; 2009 Mar; 136(3):978-89. PubMed ID: 19135996
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-5 participates in the pathogenesis of ileitis in SAMP1/Yit mice.
Takedatsu H; Mitsuyama K; Matsumoto S; Handa K; Suzuki A; Takedatsu H; Funabashi H; Okabe Y; Hara T; Toyonaga A; Sata M
Eur J Immunol; 2004 Jun; 34(6):1561-9. PubMed ID: 15162425
[TBL] [Abstract][Full Text] [Related]
14. Immunomodulation of experimental colitis: the role of NK1.1 liver lymphocytes and surrogate antigens--bystander effect.
Shlomai A; Trop S; Gotsman I; Jurim O; Diment J; Alper R; Rabbani E; Engelhardt D; Ilan Y
J Pathol; 2001 Nov; 195(4):498-507. PubMed ID: 11745683
[TBL] [Abstract][Full Text] [Related]
15. VIP balances innate and adaptive immune responses induced by specific stimulation of TLR2 and TLR4.
Arranz A; Juarranz Y; Leceta J; Gomariz RP; Martínez C
Peptides; 2008 Jun; 29(6):948-56. PubMed ID: 18359536
[TBL] [Abstract][Full Text] [Related]
16. The plant sterol guggulsterone attenuates inflammation and immune dysfunction in murine models of inflammatory bowel disease.
Mencarelli A; Renga B; Palladino G; Distrutti E; Fiorucci S
Biochem Pharmacol; 2009 Nov; 78(9):1214-23. PubMed ID: 19555671
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic treatment of experimental colitis with regulatory dendritic cells generated with vasoactive intestinal peptide.
Gonzalez-Rey E; Delgado M
Gastroenterology; 2006 Dec; 131(6):1799-811. PubMed ID: 17087944
[TBL] [Abstract][Full Text] [Related]
18. Changtai granule, a traditional Chinese drug, protects hapten-induced colitis by attenuating inflammatory and immune dysfunctions.
Liu BG; Jia XM; Cao YY; Chen SH; Gao PH; Wang Y; Jiang YY; Cao YB
J Ethnopharmacol; 2008 Jan; 115(1):1-8. PubMed ID: 17964746
[TBL] [Abstract][Full Text] [Related]
19. Blockage of tumor necrosis factor prevents intestinal mucosal inflammation through down-regulation of interleukin-23 secretion.
Liu Z; Jiu J; Liu S; Fa X; Li F; Du Y
J Autoimmun; 2007; 29(2-3):187-94. PubMed ID: 17804196
[TBL] [Abstract][Full Text] [Related]
20. Amelioration of experimental colitis by Copaxone is associated with class-II-restricted CD4 immune blocking.
Gur C; Karussis D; Golden E; Doron S; Ilan Y; Safadi R
Clin Immunol; 2006; 118(2-3):307-16. PubMed ID: 16290121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
